Evidence map›Paper›PMID 36926725›Full record

ArticleNeural regeneration research2023

Injectable collagen scaffold with human umbilical cord-derived mesenchymal stem cells promotes functional recovery in patients with spontaneous intracerebral hemorrhage: phase I clinical trial.

Xiao-Yin Li, Wu-Sheng Deng, Zi-Qi Wang, Zheng-Chao Li, Shu-Lian Chen, Zhen Song, Quan Zhang, Jin Liang, Xu-Yi Chen

Open access · greenAbstract read
In one paragraph

Article in Neural regeneration research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Xiao-Yin LiCharacteristic Medical Center of Chinese People's Armed Police Force, Tianjin Key Laboratory of Neurotrauma Repair, Tianjin, China.
Wu-Sheng DengDepartment of Neurosurgery, Dazhou Second People's Hospital, Dazhou, Sichuan Province, China.
Zi-Qi WangCharacteristic Medical Center of Chinese People's Armed Police Force, Tianjin Key Laboratory of Neurotrauma Repair; Graduate School of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Zheng-Chao LiCharacteristic Medical Center of Chinese People's Armed Police Force, Tianjin Key Laboratory of Neurotrauma Repair, Tianjin, China.
Shu-Lian ChenCharacteristic Medical Center of Chinese People's Armed Police Force, Tianjin Key Laboratory of Neurotrauma Repair, Tianjin, China.
Zhen SongCharacteristic Medical Center of Chinese People's Armed Police Force, Tianjin Key Laboratory of Neurotrauma Repair; Graduate School of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Quan ZhangCharacteristic Medical Center of Chinese People's Armed Police Force, Tianjin Key Laboratory of Neurotrauma Repair, Tianjin, China.
Jin LiangCharacteristic Medical Center of Chinese People's Armed Police Force, Tianjin Key Laboratory of Neurotrauma Repair, Tianjin, China.
Xu-Yi ChenCharacteristic Medical Center of Chinese People's Armed Police Force, Tianjin Key Laboratory of Neurotrauma Repair, Tianjin, China.
Chinese People's Armed Police Force Medical College Affiliated Hospital · CNTianjin University of Traditional Chinese Medicine · CNDazhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Animal experiments have shown that injectable collagen scaffold with human umbilical cord-derived mesenchymal stem cells can promote recovery from spinal cord injury. To investigate whether injectable collagen scaffold with human umbilical cord-derived mesenchymal stem cells can be used to treat spontaneous intracerebral hemorrhage, this non-randomized phase I clinical trial recruited patients who met the inclusion criteria and did not meet the exclusion criteria of spontaneous intracerebral hemorrhage treated in the Characteristic Medical Center of Chinese People's Armed Police Force from May 2016 to December 2020. Patients were divided into three groups according to the clinical situation and patient benefit: control (n = 18), human umbilical cord-derived mesenchymal stem cells (n = 4), and combination (n = 8). The control group did not receive any transplantation. The human umbilical cord-derived mesenchymal stem cells group received human umbilical cord-derived mesenchymal stem cell transplantation. The combination group received injectable collagen scaffold with human umbilical cord-derived mesenchymal stem cells. Patients who received injectable collagen scaffold with human umbilical cord-derived mesenchymal stem cells had more remarkable improvements in activities of daily living and cognitive function and smaller foci of intracerebral hemorrhage-related encephalomalacia. Severe adverse events associated with cell transplantation were not observed. Injectable collagen scaffold with human umbilical cord-derived mesenchymal stem cells appears to have great potential treating spontaneous intracerebral hemorrhage.

Indexed as

clinical trial; collagen scaffold; efficacy; human umbilical cord-derived mesenchymal stem cells; humansafe; neurological recovery; spontaneous intracerebral hemorrhage; transplantation

Identifiers

PMID36926725
PMCPMC10233785
OpenAlexW4327678288

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.